<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679351</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/18/221</org_study_id>
    <nct_id>NCT03679351</nct_id>
  </id_info>
  <brief_title>&quot;FU-IFM2009&quot; Database Post IFM/DFCI 2009 Study</brief_title>
  <acronym>DB-FU-IFM2009</acronym>
  <official_title>&quot;Follow Up-Intergroupe Francophone du My√©lome 2009&quot; Database Post IFM/DFCI 2009 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extension of patient follow-up of the IFM/DFCI 2009 study over a period of 4 years (that is,
      from 01 December 2016 to 30 November 2020) during which patients will be followed up in the
      normal course of care and according to the usual care of the centers, with collection of the
      needed data about twice a year by the investigators
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>4 years</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall long-term survival</measure>
    <time_frame>4 years</time_frame>
    <description>number of deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary primary malignancies</measure>
    <time_frame>4 years</time_frame>
    <description>number of secondary primary malignancies</description>
  </secondary_outcome>
  <enrollment type="Anticipated">675</enrollment>
  <condition>Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been already randomized in the IFM/DFCI 2009 study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient randomized in the IFM/DFCI 2009 study.

          -  Patient still alive must give their non-opposition to the post IFM/DFCI 2009 study
             data collection until 30 November 2020

          -  Patient non-opposition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Attal, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hosptial toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel ATTAL, MD PhD</last_name>
    <phone>05 31 15 50 01</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.attal@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura BOGDANOVITCH</last_name>
    <phone>05 61 77 84 37</phone>
    <phone_ext>+33</phone_ext>
    <email>bogdanovitch.l@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel ATTAL, PhD</last_name>
      <phone>05 31 15 50 01</phone>
      <phone_ext>+33</phone_ext>
      <email>michel.attal@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

